Marker Therapeutics (MRKR) Expected to Release Earnings on Thursday

Marker Therapeutics (NASDAQ:MRKR) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Marker Therapeutics to post earnings of ($0.25) per share and revenue of $0.6820 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The firm had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.78 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. On average, analysts expect Marker Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Marker Therapeutics Price Performance

MRKR opened at $1.15 on Thursday. The firm has a market capitalization of $19.09 million, a P/E ratio of -1.88 and a beta of 1.50. Marker Therapeutics has a one year low of $0.81 and a one year high of $2.46. The company has a fifty day moving average price of $1.37 and a 200-day moving average price of $1.46.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MRKR. Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a research report on Wednesday, May 20th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $10.00.

Hedge Funds Weigh In On Marker Therapeutics

Large investors have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in Marker Therapeutics in the 2nd quarter worth approximately $33,000. Virtu Financial LLC purchased a new stake in Marker Therapeutics in the third quarter worth approximately $25,000. Two Sigma Investments LP bought a new position in Marker Therapeutics during the third quarter valued at approximately $33,000. XTX Topco Ltd grew its position in Marker Therapeutics by 166.6% during the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after acquiring an additional 36,269 shares during the last quarter. Finally, LPL Financial LLC raised its stake in shares of Marker Therapeutics by 41.7% during the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after acquiring an additional 24,500 shares in the last quarter. 22.39% of the stock is owned by hedge funds and other institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.